Precose Related Published Studies
Well-designed clinical trials related to Precose (Acarbose)
[A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus] [2009.04]
Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. [2009.02]
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. [2009.02]
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. [2009.01]
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. [2008.10]
Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. [2008.06]
[A multicenter randomized controlled clinical trial on blood glucose lowering effects of domestic Acarbose (capsule) in type 2 diabetic patients] [2007.11]
Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. [2007.08]
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. [2007.07]
Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes. [2007.04]
Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. [2006.10]
Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. [2006.07]
Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. [2006.07]
Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. [2006.03]
Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. [2006.01]
Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. [2006]
Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. [2005.09]
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. [2005.04]
A randomized controlled trial of acarbose in hepatic encephalopathy. [2005.02]
Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. [2005.01]
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome. [2005]
Effects of acarbose in beta-thalassaemia major patients with normal glucose tolerance and hyperinsulinism. [2004.12]
[Cost-effectiveness analysis of acarbose in the treatment of patients with impaired glucose tolerance] [2004.11]
Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. [2004.10]
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. [2004.06]
The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. [2004.06]
Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level. [2004.05]
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. [2004.05]
Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. [2004.02]
Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial. [2004.01]
The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. [2004.01]
Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. [2003.09]
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. [2003.08]
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. [2003.07.23]
Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas. [2003.07]
Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study. [2003.05]
Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. [2003.02]
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. [2003.01]
Acarbose in the treatment of elderly patients with type 2 diabetes. [2003.01]
Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin? [2002.10]
Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. [2002.08]
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. [2002.06.15]
The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. [2002.06]
Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. [2002.06]
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. [2002.03]
Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. [2002.02]
Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. [2002]
Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. [2001.12]
Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. [2001.09]
Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. [2001.02]
Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. [2001]
Biomarkers of human colonic cell growth are influenced differently by a history of colonic neoplasia and the consumption of acarbose. [2000.11]
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. [2000.09]
Effect of acarbose on insulin sensitivity in elderly patients with diabetes. [2000.08]
Acarbose raises serum butyrate in human subjects with impaired glucose tolerance. [2000.07]
Effect of the alpha-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus. [2000.04.15]
Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes. [2000.02]
Treatment of familial hypertriglyceridaemia with acarbose. [2000.01]
Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group. [2000.01]
Lack of interaction between thioctic acid, glibenclamide and acarbose. [1999.12]
Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. [1999.09]
Effects of acarbose treatment in Type 2 diabetic patients under dietary training: a multicentre, double-blind, placebo-controlled, 2-year study. [1999.08]
Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. [1999.07]
Use of acarbose for eliminating the interval between meal consumption and insulin injection in patients with Type 1 diabetes. [1999.06]
Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients. [1999.06]
The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. [1999.06]
Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. [1999.06]
A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44) [1999.06]
Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? [1999.03]
Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. [1999.03]
Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. [1999.01]
[Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose] [1999.01]
Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. [1998.12]
Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. [1998.12]
No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. [1998.10]
Impairment of absorption of digoxin by acarbose. [1998.07]
Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study. [1998.07]
An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group. [1998.07]
Lowering glycemic index of food by acarbose and Plantago psyllium mucilage. [1998.06]
Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. [1998.06]
Effects of beano on the tolerability and pharmacodynamics of acarbose. [1998.05]
The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. [1998]
Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. [1997.12]
Effect of acarbose and simultaneous antacid therapy on blood glucose. [1997.10]
Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group. [1997.10]
Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. [1997.09]
Glibenclamide, but not acarbose, increases leptin concentrations parallel to changes in insulin in subjects with NIDDM. [1997.09]
Comparison of the effects of acarbose and voglibose in healthy subjects. [1997.07]
Acarbose enhances human colonic butyrate production. [1997.05]
Acarbose in the treatment of type I diabetes. [1997.03]
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. [1996.11]
Effects of acarbose on fecal nutrients, colonic pH, and short-chain fatty acids and rectal proliferative indices. [1996.09]
Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. [1996.04]
A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. [1996.03]
The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. [1996]
The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. [1995.11]
Clinical experience with acarbose: results of a Canadian multicentre study. [1995.08]
Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial. [1995.08]
A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. [1995.07]
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. [1995.05]
One-year acarbose treatment raises fasting serum acetate in diabetic patients. [1995.02]
|
